Trials / Completed
CompletedNCT00595049
Pulmonary Artery Remodelling With Bosentan
Open Label, Non Comparative Study to Investigate the Effect of Bosentan on Pulmonary Artery Remodelling in Pulmonary Arterial Hypertension (PAH).
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Actelion · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to investigate whether bosentan (Tracleer®) affects the wall thickness of the pulmonary arteries in patients with idiopathic pulmonary arterial hypertension (iPAH) and PAH related to systemic sclerosis (PAH-SSc). The second purpose is to investigate if bosentan affects the enlargement of small vessels in the lungs in response to natural chemicals in patients with iPAH and PAH-SSc.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bosentan | Bosentan 62.5 mg bid for 4 weeks, then 125 mg bid |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2008-12-01
- Completion
- 2010-06-01
- First posted
- 2008-01-16
- Last updated
- 2025-02-03
Source: ClinicalTrials.gov record NCT00595049. Inclusion in this directory is not an endorsement.